Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach
| Autor: | Hyung Mo Sung, Matthew W. Specht, Marco A. Grados, Diandra Fortune |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Central Nervous System
Candidate gene Obsessive-Compulsive Disorder biology business.industry SLC1A1 Glutamic Acid Genome-wide association study Pharmacology Bioinformatics medicine.disease Riluzole Acamprosate Schizophrenia Drug Discovery biology.protein Medicine Animals Humans business Neuropharmacology Pharmacogenetics medicine.drug |
| Zdroj: | Expert opinion on drug discovery. 8(12) |
| ISSN: | 1746-045X |
| Popis: | Neuropharmacology research in glutamate-modulating drugs supports their development and use in the management of neuropsychiatric disorders, including major depression, Alzheimer's disorder and schizophrenia. Concomitantly, there is a growing use of these agents used in the treatment of obsessive-compulsive disorder (OCD).This article provides a review of glutamate-modulating drugs used in the treatment of OCD. Specifically, the authors examine riluzole, N-acetylcysteine, d-cycloserine, glycine, ketamine, memantine and acamprosate as treatments. Furthermore, recent genetic epidemiology research findings are presented with a focus on the positional candidate genes SLC1A1 (a glutamate transporter), ADAR3 (an RNA-editing enzyme), RYR3 (a Ca(2+) channel), PBX1 (a homeobox transcription factor) and a GWAS candidate gene, DLGAP1 (a protein interacting with post-synaptic density). These genetic findings are submitted to a curated bioinformatics database to conform a biological network for discerning potential pharmacological targets.In the genetically informed network, known genes and identified key connecting components, including DLG4 (a developmental gene), PSD-95 (a synaptic scaffolding protein) and PSEN1 (presenilin, a regulator of secretase), conform a group of potential pharmacological targets. These potential targets can be explored, in the future, to deliver new therapeutic approaches to OCD. There is also the need to develop a better understanding of neuroprotective mechanisms as a foundation for future OCD drug discovery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|